MiniMed Group, Inc. began independent operations in early 2026 following its separation from Medtronic, debuting the MiniMed Flex™, the smallest smartphone-controlled insulin pump cleared by the FDA. Despite promising product innovation, initial standalone results show a net loss and negative cash flow reflecting substantial R&D and commercialization investments. Operational continuity is supported by transitional agreements with Medtronic, while capital structure includes a $500 million revolving credit facility. Near-term focus will be on commercial execution and managing leverage amid investment-driven losses.